Odonate Therapeutics, Inc. ODTC
We take great care to ensure that the data presented and summarized in this overview for Odonate Therapeutics, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in ODTC
Top Purchases
Top Sells
About ODTC
Odonate Therapeutics, Inc., a pharmaceutical company, develops therapeutics for the treatment of cancer. It is developing tesetaxel, an orally administered chemotherapy agent, which is in Phase III clinical study for patients with metastatic breast cancer. The company was founded in 2013 and is based in New York, New York.
Insider Transactions at ODTC
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 10
2021
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
5,545,000
-95.09%
|
$5,545,000
$1.61 P/Share
|
|
Dec 09
2021
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
156,669
-2.75%
|
$156,669
$1.82 P/Share
|
|
Dec 01
2021
|
Eco R1 Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
185,941
-3.16%
|
$185,941
$1.66 P/Share
|
|
Dec 01
2021
|
Eco R1 Capital, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
185,941
+3.16%
|
$185,941
$1.66 P/Share
|
|
Nov 24
2021
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-4.54%
|
$200,000
$1.57 P/Share
|
|
Nov 22
2021
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
200,000
-4.34%
|
$200,000
$1.55 P/Share
|
|
Nov 19
2021
|
Aaron I. Davis Director |
SELL
Open market or private sale
|
Indirect |
150,000
-3.15%
|
$150,000
$1.84 P/Share
|
|
Nov 19
2021
|
Aaron I. Davis Director |
SELL
Open market or private sale
|
Direct |
30,000
-6.31%
|
$30,000
$1.92 P/Share
|
|
Nov 19
2021
|
Tang Kevin C Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
365,289
-2.78%
|
$365,289
$1.92 P/Share
|
|
Nov 19
2021
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
150,000
-3.15%
|
$150,000
$1.84 P/Share
|
|
Nov 18
2021
|
Aaron I. Davis Director |
SELL
Open market or private sale
|
Indirect |
250,000
-4.99%
|
$250,000
$1.95 P/Share
|
|
Nov 18
2021
|
Tang Kevin C Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
1,094,265
-2.63%
|
$1,094,265
$1.91 P/Share
|
|
Nov 18
2021
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
250,000
-4.99%
|
$250,000
$1.95 P/Share
|
|
Nov 17
2021
|
Aaron I. Davis Director |
SELL
Open market or private sale
|
Indirect |
600,000
-10.7%
|
$1,200,000
$2.17 P/Share
|
|
Nov 17
2021
|
Aaron I. Davis Director |
SELL
Open market or private sale
|
Direct |
170,000
-26.33%
|
$340,000
$2.23 P/Share
|
|
Nov 17
2021
|
Tang Kevin C Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
1,287,577
-2.14%
|
$2,575,154
$2.22 P/Share
|
|
Nov 17
2021
|
Boxer Capital, LLC > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
600,000
-10.7%
|
$1,200,000
$2.17 P/Share
|
|
Mar 15
2021
|
Joseph P O'Connell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
99
+2.67%
|
$1,584
$16.22 P/Share
|
|
Mar 15
2021
|
Michael S Hearne Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
37
+1.39%
|
$592
$16.22 P/Share
|
|
Feb 26
2021
|
Joseph P O'Connell Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
90
+2.5%
|
$1,530
$17.89 P/Share
|
Last 12 Months Summary
Buy / Acquisition
0
Shares
From
0
Insiders
Sell / Disposition
0
Shares
From
0
Insiders